Brokerages Set CeriBell, Inc. (NASDAQ:CBLL) Price Target at $24.67

CeriBell, Inc. (NASDAQ:CBLL) has earned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $24.6667.

A number of analysts recently weighed in on CBLL shares. TD Cowen reissued a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Canaccord Genuity Group lifted their price objective on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, BTIG Research reiterated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th.

CeriBell Stock Performance

Shares of NASDAQ CBLL opened at $18.57 on Friday. The firm has a market capitalization of $698.97 million, a price-to-earnings ratio of -12.63 and a beta of 0.94. CeriBell has a one year low of $10.01 and a one year high of $24.33. The business has a fifty day simple moving average of $19.39 and a 200 day simple moving average of $17.37. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The firm had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. Sell-side analysts expect that CeriBell will post -2.46 EPS for the current year.

Insider Buying and Selling

In other news, CTO Raymond Woo sold 8,087 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $18.25, for a total value of $147,587.75. Following the sale, the chief technology officer owned 166,912 shares of the company’s stock, valued at approximately $3,046,144. This represents a 4.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Josef Parvizi sold 16,714 shares of CeriBell stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $20.27, for a total transaction of $338,792.78. Following the transaction, the director directly owned 722,652 shares of the company’s stock, valued at $14,648,156.04. This represents a 2.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 190,015 shares of company stock valued at $3,866,583. 20.10% of the stock is currently owned by insiders.

Institutional Trading of CeriBell

A number of institutional investors have recently bought and sold shares of CBLL. Geode Capital Management LLC grew its position in CeriBell by 55.4% in the 2nd quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after purchasing an additional 159,698 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of CeriBell by 161.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after buying an additional 3,502 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of CeriBell during the second quarter valued at about $266,000. JPMorgan Chase & Co. increased its position in shares of CeriBell by 6,424.8% during the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after acquiring an additional 374,179 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of CeriBell by 109.9% in the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock worth $614,000 after acquiring an additional 17,177 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.